HOME > BUSINESS
BUSINESS
- Lixiana Waging Hand-to-Hand Combat with Xarelto in DOAC Market: Encise FY2018 Snapshot
April 8, 2019
- Novartis’ Eylea Challenger Could Reach Filing This Year for 2020 Launch
April 8, 2019
- 5 Industry-Academia Partners Tie Up for Research to Commercialize Renal Regenerative Medicine
April 8, 2019
- Japan Ethical Drug Sales Up 0.2% in February: Crecon
April 8, 2019
- FDA Accepts NDA Resubmission for Parkinson’s Drug Istradefylline: Kyowa Kirin
April 8, 2019
- Janssen Files Darzalex for Combination Therapy for Treatment-Naïve Multiple Myeloma in Japan
April 8, 2019
- FDA Extends Quizartinib Review by 3 Months: Daiichi Sankyo
April 5, 2019
- Cancer Drug Pexidartinib Filed in Europe: Daiichi Sankyo
April 5, 2019
- Clinigen Gets Japan Rights to Intracerebroventricular Form of Hunter Syndrome Drug Idursulfase Beta
April 5, 2019
- Lilly Japan Nets 263 Billion Yen in 2018, Now 6th in Sales Ranking
April 4, 2019
- Cefazolin Generic Shortage Raises Worries of Supply Crunch after G1 LLP Withdrawals
April 4, 2019
- EquMet Becomes Best Seller for Novartis Japan in FY2018
April 4, 2019
- Japan Pharma Market Skids 1.4% in FY2018: Encise
April 4, 2019
- Gilead’s Biktarvy to Make Japan Debut on April 8
April 4, 2019
- Axcelead Now Independent from Takeda
April 3, 2019
- Kowa Sues Towa over Livalo Generics, Demands 4.5 Billion Yen in Additional Damages
April 3, 2019
- Telomelysin/Keytruda Combo Shows No Dose-Limiting Toxicities in Interim PIa Data: Oncolys
April 3, 2019
- Xospata Significantly Extends OS in PIII Study in FLT3-Mutated AML: Astellas
April 3, 2019
- Sumitomo Dainippon Files Rethio for Conditioning Treatment Prior to HSCT for Malignant Lymphoma
April 3, 2019
- Nichi-Iko Takes Over Futhan from Torii
April 2, 2019
ページ
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
